Regeneron Pharmaceuticals Inc (NASDAQ:REGN)
| 660.63 Delayed Data As of May 20 |  +3.99 / +0.61%Today’s Change | 492.13 Today|||52-Week Range 747.42 | +4.61% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $72.6B |
Company Description
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
Contact Information
Regeneron Pharmaceuticals, Inc. 777 Old Saw Mill River Road Tarrytown New York 10591-6707 |
Employees
Shareholders
| Mutual fund holders | 59.46% |
| Other institutional | 29.09% |
| Individual stakeholders | 24.52% |
Top Executives
| Leonard S. Schleifer | Co-President, Chief Executive Officer & Director |
| George Damis Yancopoulos | Co-President, Director & Chief Scientific Officer |
| Patrice Gilooly | Senior VP-Quality Assurance & Operations |
| Robert E. Landry | Chief Financial Officer & Executive VP-Finance |
| Neil Stahl | Executive VP-Research & Development |
